Akatinol Memantine tabs 10mg #30

Akatinol Memantine instruction

You can buy Akatinol Memantine here

To buy other dosage please contact us

Composition

1 tablet can include 5 mg / 10 mg / 15 mg or 20 mg memantine.
The additional composition of the substances in the tablet differs depending on the mass content of the active ingredient in it.

Form of issue

Drug Akatinol Memantine is produced in the form of tablets in the following secondary packages: 10 mg - No. 30 or No. 90; 20 mg - №28, №56 or №98. Also, one of the forms of release of the drug is a tabletset No. 28, comprising 7 tablets with a different mass content of memantine (5 mg, 10 mg, 15 mg, 20 mg).

pharmachologic effect

Anti-water (for the therapy of dementia).

Pharmacodynamics and pharmacokinetics

Akatinol Memantine is a medicinal preparation that is a noncompetitive NMDA antagonist (N-methyl-D-aspartate). The effectiveness of memantine is developed due to its effect on glutamate ionotropic NMDA receptors, as a result of which the modulating effect of the drug directed to the glutamatergic system is manifested.
Memantine actively participates in the processes of ion transport regulation, normalization of membrane potential, blocking of calcium channels. Thanks to the effects of the drug, the spread of nerve impulses improves, the cognitive functionality of the brain increases and the daily activity of the patient increases.
Oral administration of memantine leads to its rapid and complete absorption. During the time from 2 to 6 hours, a plasma Cmax of the drug is achieved. With normal renal function, cumulation of the drug is not observed. T1 / 2 of two excretion phases is 4-9 hours and 40-65 hours, respectively. Excretion is carried out by the kidneys.

Indications for use

Akatinol Memantine tablets are prescribed for the purpose of maintenance therapy for mixed, vascular dementia, and dementia of Alzheimer's type (Alzheimer's disease) of any severity.

Contraindications

Akatinol Memantine is contraindicated in the administration of:
    personal hypersensitivity to the active ingredient and additional ingredients of the tablets;
    breastfeeding;
    expressed violations of renal function;
    pregnancy;
    up to 18 years (insufficiently verified data).
Care should be given to the drug when:
    convulsions (including indications in the anamnesis);
    thyrotoxicosis;
    heart failure;
    epilepsy;
    myocardial infarction.

Side effects

When taking the drug in some patients observed the development of negative side effects, including:
    headache;
    fast fatigue;
    constipation;
    fungal infections;
    dizziness;
    venous thrombosis;
    drowsiness;
    violation of gait;
    nausea / vomiting;
    confusion of consciousness;
    hypertension;
    hallucinations (with severe degree of dementia);
    thromboembolism;
    psychotic reactions (very rarely);
    pancreatitis (very rarely);
    convulsions (very rarely).

Akatinol Memantine, instructions for use (Method and dosage)

Tablets of the therapeutic agent Akatinol Memantine are intended for oral intake during meals.
Instructions for use Akatinol Memantine assumes an individual selection of dosage regimen for each individual patient who has reached the age of 18 years (for young children, taking these tablets is not recommended), with the choice of the optimal dosage in the course of weekly increases in the doses taken by him.
Supportive therapy of dementia states is recommended to begin with the patient's intake during the first week of a minimum daily dose of 5 mg. Subsequently, every 7 days, the daily dosage is increased by 5 mg, reaching the optimal daily dose of 20 mg by the fourth week of treatment. If there is an acute need, a gradual (weekly 5 mg dose) increase in the daily dosage to 30 mg is permissible.

Overdose

The negative consequences of taking overestimated doses of Akatinol Memantine may be due to the appearance or intensification of side effects inherent in this drug.
The complex of therapeutic measures for leveling negative overdose phenomena includes: purification of the gastrointestinal tract, sorbents intake and subsequent symptomatic treatment.

Interaction

The combined use of anticholinergic medicines, dopamine agonists and L-dopa preparations may cause an increase in their effect.
Parallel administration with neuroleptics and barbiturates can reduce their effectiveness.
When taken together with Baclofen or Dantrolenum, it is possible to reduce or increase their effect, which may require individual selection of doses of these drugs.
It should not be allowed combined treatment with Dexomethorphan, Ketamine and amantadine.
Simultaneous administration with kinin, cimetidine, nicotine, kinidine and procainamide may increase their plasma concentrations.
With a parallel intake with hydrochlorothiazide, it is possible to lower its serum level.

Storage conditions

Not exceeding 25 ° С.
Shelf life - 4 years.

special instructions

In patients with Alzheimer's disease, especially in the moderate and severe stages of dementia, violations often occur that do not allow them to adequately manage complex mechanisms and motor vehicles. In addition, the use of memantine is able to change the rate of their reaction. In this regard, patients undergoing therapy with Akatin Memantine on an outpatient basis must be careful in managing complex mechanisms and motor vehicles.

Children

With the official instruction, taking the drug by patients under 18 is contraindicated.

With alcohol

When passing therapy, you should avoid taking any drinks that include alcohol.

In pregnancy and lactation

Akatinol Memantine is contraindicated in prescribing to lactating and pregnant women.

Reviews about Akatinol Memantine

In the Internet on the drug Akatinol Memantine, you can find both positive and negative feedback. For elderly patients with Alzheimer's disease or another type of dementia, this drug often becomes irreplaceable, but, unfortunately, can only slow down the progress of the disease and somewhat improve the overall condition of the patient. At this time, funds completely rid the person of such ailments, unfortunately, has not yet been invented.
Another frequently discussed side of Akatinol Memantine, despite contraindications in the official instruction, is its administration to children, with the aim of treating problems of their mental development. In this regard, the reviews about Akatinol Memantine for children are the most diverse, ranging from highly positive and ending sharply negative. Also, there are frequent evidence of the initially positive effect of the drug on the child followed by a sharp "pullback", returning the small patient to its original state, and sometimes even exacerbating it. In any case, the decision to prescribe a particular medicine or treatment procedures for children rests with their leading pediatricians and parents, who must take this issue with full responsibility and work together on the existing problem.